Journal article
Treatment of osteosarcoma at first recurrence after contemporary therapy : The memorial sloan-kettering cancer center experience
Cancer, Vol.104(10), pp.2214-2221
2005
DOI: 10.1002/cncr.21417
PMID: 16206297
Abstract
Background: Overall survival after recurrence of osteosarcoma (OS) is < 30%. The authors reported their experience treating recurrent OS at the time of first recurrence (R1).
Methods: Patients with high-grade OS who achieved complete disease remission (CR) after primary surgery and chemotherapy, and patients who were treated at R1 at Memorial Sloan-Kettering Cancer Center (New York, NY) after 1990 were analyzed by retrospective chart review.
Results: For 43 eligible patients, the median time to R1 from initial diagnosis was 21.7 months (range, 4.6-135.7 mos). The lungs were the most common sites of disease recurrence (n = 33 of 43). With a median follow-up of 15.2 months (range, 0.7-158.3 mos) after R1, 15 of 43 (35%) patients were alive. Four of 43 patients were treated with surgery alone (3 patients were alive and 1 had died of progressive disease at the time of last follow-up). Due to unresectable disease, eight patients received only chemotherapy, none of whom survived. For patients with disease recurrence treated with chemotherapy and surgery (n = 31), 22 patients achieved a second CR (CR2). Nine patients were alive and in disease remission (29%) at the time of last follow-up. Twenty-three patients received ifosfamide as part of their retrieval regimen. Of the 18 who achieved a CR2, 8 experienced disease recurrence, 7 remain alive in CR2, and 3 died due to toxicity. Eight patients did not receive ifosfamide. Of these, 4 achieved a CR2 but 3 subsequently experienced disease recurrence.
Conclusions: At R1, 22 of 31 patients achieved a CR2 with aggressive surgery and chemotherapy. The majority of these patients subsequently developed a disease recurrence. Patients appeared to benefit from the addition of ifosfamide to their retrieval regimens. In the end, the role of chemotherapy in recurrent OS continues to remain undefined.
Details
- Title: Subtitle
- Treatment of osteosarcoma at first recurrence after contemporary therapy : The memorial sloan-kettering cancer center experience
- Creators
- Alexander J CHOU - Department of Pediatrics, Memorial Sloan-Ket tering Cancer Center, New York, New York, United StatesPamela R MEROLA - Department of Pediatrics, Memorial Sloan-Ket tering Cancer Center, New York, New York, United StatesLeonard H WEXLER - Department of Pediatrics, Memorial Sloan-Ket tering Cancer Center, New York, New York, United StatesRichard G GORLICK - Section of Hematology/Oncology, Department of Pediatrics, The Children's Hospital at Montefiore, Bronx, New York, United StatesYatin M VYAS - Department of Pediatrics, Memorial Sloan-Ket tering Cancer Center, New York, New York, United StatesJohn H HEALEY - Department of Surgery, Memorial Sloan-Ketter ing Cancer Center, New York, New York, United StatesMichael P LAQUAGLIA - Department of Surgery, Memorial Sloan-Ketter ing Cancer Center, New York, New York, United StatesAndrew G HUVOS - Department of Pathology, Memorial Sloan-Ket tering Cancer Center, New York, New York, United StatesPaul A MEYERS - Department of Pediatrics, Memorial Sloan-Ket tering Cancer Center, New York, New York, United States
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.104(10), pp.2214-2221
- DOI
- 10.1002/cncr.21417
- PMID
- 16206297
- NLM abbreviation
- Cancer
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Publisher
- Wiley-Liss
- Language
- English
- Date published
- 2005
- Academic Unit
- Stead Family Department of Pediatrics
- Record Identifier
- 9984093598502771
Metrics
36 Record Views